Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03JZC
|
|||
| Former ID |
DIB016132
|
|||
| Drug Name |
PF-06263507
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oncotrophoblast glycoprotein 5T4 (TPBG) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01891669) A Study Of PF-06263507 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 751006). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.